Loading...

Estrella Immunopharma, Inc.

ESLAWNASDAQ
Healthcare
Biotechnology
$0.04
$0.00(0.83%)

Estrella Immunopharma, Inc. ESLAW Peers

See (ESLAW) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ESLAW$0.04+0.83%1.3MN/AN/AN/A
VRTX$445.20+0.88%114.3B-115.94-$3.84N/A
REGN$525.00+0.77%55.7B13.34$39.35+0.17%
SGEN$228.74-0.07%43.2B-57.19-$4.00N/A
ALNY$326.09+1.01%42.5B-154.55-$2.11N/A
ARGX$551.22-1.59%33.7B33.63$16.39N/A
BNTX$106.47-0.23%25.6B-29.09-$3.66N/A
RPRX$36.03+0.45%20.3B14.71$2.45+2.42%
BGNE$184.71+0.49%20.2B-22.55-$8.19N/A
DNA-WT$0.27-2.76%18.7BN/AN/AN/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ESLAW vs VRTX Comparison

ESLAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ESLAW stands at 1.3M. In comparison, VRTX has a market cap of 114.3B. Regarding current trading prices, ESLAW is priced at $0.04, while VRTX trades at $445.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ESLAW currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is -115.94. In terms of profitability, ESLAW's ROE is -1.56%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, ESLAW is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ESLAW.

Stock Price Comparison

Loading...

Frequently Asked Questions

;